Clarivate PLC (NYSE:CLVT) acquired Bioinfogate, an analytics solutions provider in the life sciences and producer of the OFF-X portal.
The financial terms of the transaction remain undisclosed.
The?Bioinfogate?OFF-X™?portal is a cutting-edge safety intelligence solution aimed at empowering pharmaceutical organizations to identify toxicology and safety signals, mitigate safety liabilities and de-risk early-stage assets. It is one of the largest?translational safety and toxicity?portals, featuring over 1,200,000 safety alerts corresponding to over 23,000 drugs and biologics and more than 15,000 targets of pharmacological interest.
As a leading provider of trusted information and insights to accelerate innovation, Clarivate offerings include a comprehensive suite of research intelligence solutions coupled with deep domain expertise. The acquisition of?Bioinfogate?will fill a critical need for drug toxicity data and translational safety intelligence across all stages of drug R&D.
This follows a previous acquisition from the Prous family of companies. Clarivate acquired the Integrity product (now known as Cortellis Drug Discovery Intelligence from Prous Science in 2007. In addition, through a 2019 partnership with Bioinfogate, Clarivate integrated OFF-X translational safety intelligence data with Cortellis products, including Cortellis Drug Discovery and Cortellis Competitive Intelligence
Experts say the purchase of Bioinfogate will fill a critical need for drug toxicity data and translational safety intelligence across all stages of drug R&D.
With previously acquired Cortellis, OFF-X will provide critical translational safety intelligence alongside a robust drug pipeline and clinical research information.
Beyond Cortellis, OFF-X will strengthen other Clarivate products and services, including the Web of Science, the publisher-independent global citation database.
CLVT shares took on 33 cents, or 1.4%, to $23.49.
Related Stories
